Ikarovec is a pre-clinical phase gene therapy company focused on developing innovative treatments for common eye diseases. Their technology is designed to target multiple disease pathways, enhancing the efficacy of treatments aimed at restoring sight and preventing blindness. The company’s lead research programs include gene therapy treatments for geographic atrophy and neovascular (wet-form) age-related macular degeneration. Additionally, Ikarovec is exploring earlier-stage programs for diabetic macular edema and ocular hypertension, which is a significant risk factor for glaucoma.

The core of Ikarovec's approach lies in gene therapy, a technique that enables the introduction of DNA into target cells in the eye through gene transfer. This DNA instructs the cells to produce proteins that can effectively treat specific diseases. Unlike conventional therapies that often require repeated injections or daily eye drops, Ikarovec's gene therapies typically necessitate only a single injection, with therapeutic effects potentially lasting for many years. This method also allows for the introduction of genetic information coding for multiple proteins within a single treatment, thereby addressing various disease pathways and improving overall treatment efficacy compared to traditional single-target drugs.

United Kingdom

Ikarovec is a UK-based biotech gene therapy company with a focus in ophthalmology. Ikarovec was originally formed as a spin-out from the biotechnology company.

Ikarovec

Company Details